Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 16 studies | 29% ± 13% | |
fibroblast | 11 studies | 30% ± 12% | |
smooth muscle cell | 9 studies | 31% ± 8% | |
glutamatergic neuron | 6 studies | 44% ± 24% | |
interneuron | 5 studies | 41% ± 24% | |
retinal ganglion cell | 5 studies | 32% ± 14% | |
myofibroblast cell | 5 studies | 24% ± 11% | |
Mueller cell | 5 studies | 32% ± 13% | |
retina horizontal cell | 5 studies | 23% ± 9% | |
GABAergic neuron | 5 studies | 47% ± 18% | |
granule cell | 4 studies | 36% ± 8% | |
amacrine cell | 4 studies | 24% ± 4% | |
astrocyte | 4 studies | 27% ± 11% | |
GABAergic interneuron | 3 studies | 25% ± 7% | |
epithelial cell | 3 studies | 19% ± 3% | |
neuron | 3 studies | 21% ± 3% | |
oligodendrocyte precursor cell | 3 studies | 22% ± 4% | |
pericyte | 3 studies | 32% ± 17% | |
GABAergic amacrine cell | 3 studies | 39% ± 10% | |
OFF-bipolar cell | 3 studies | 31% ± 14% | |
endothelial cell of lymphatic vessel | 3 studies | 19% ± 3% | |
lymphocyte | 3 studies | 30% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 99% | 4640.61 | 242 / 245 | 100% | 14.18 | 502 / 502 |
skin | 99% | 5784.58 | 1783 / 1809 | 100% | 18.04 | 471 / 472 |
breast | 96% | 3059.50 | 441 / 459 | 99% | 10.39 | 1109 / 1118 |
lung | 100% | 9379.45 | 576 / 578 | 93% | 6.86 | 1073 / 1155 |
uterus | 99% | 5330.15 | 168 / 170 | 86% | 6.51 | 393 / 459 |
bladder | 90% | 14499.10 | 19 / 21 | 86% | 6.80 | 434 / 504 |
brain | 75% | 4043.84 | 1974 / 2642 | 98% | 7.80 | 693 / 705 |
esophagus | 78% | 12209.63 | 1133 / 1445 | 93% | 7.00 | 171 / 183 |
intestine | 84% | 5749.17 | 814 / 966 | 85% | 4.60 | 447 / 527 |
thymus | 64% | 1510.09 | 419 / 653 | 99% | 7.77 | 596 / 605 |
stomach | 67% | 3829.46 | 241 / 359 | 90% | 5.66 | 258 / 286 |
adrenal gland | 61% | 1307.98 | 158 / 258 | 92% | 10.92 | 211 / 230 |
kidney | 61% | 1417.47 | 54 / 89 | 91% | 9.67 | 816 / 901 |
ovary | 62% | 1520.01 | 112 / 180 | 87% | 5.33 | 372 / 430 |
pancreas | 6% | 122.62 | 20 / 328 | 96% | 6.78 | 170 / 178 |
blood vessel | 100% | 20212.59 | 1335 / 1335 | 0% | 0 | 0 / 0 |
spleen | 99% | 4012.37 | 239 / 241 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 12.28 | 79 / 80 |
adipose | 98% | 3798.51 | 1176 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 93% | 5.09 | 42 / 45 |
lymph node | 0% | 0 | 0 / 0 | 93% | 8.26 | 27 / 29 |
liver | 6% | 121.35 | 14 / 226 | 68% | 2.64 | 277 / 406 |
muscle | 66% | 1927.64 | 526 / 803 | 0% | 0 | 0 / 0 |
heart | 50% | 1038.26 | 431 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 7% | 133.72 | 64 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006382 | Biological process | adenosine to inosine editing |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_0021965 | Biological process | spinal cord ventral commissure morphogenesis |
GO_0006397 | Biological process | mRNA processing |
GO_0016553 | Biological process | base conversion or substitution editing |
GO_0060415 | Biological process | muscle tissue morphogenesis |
GO_0044387 | Biological process | negative regulation of protein kinase activity by regulation of protein phosphorylation |
GO_0061744 | Biological process | motor behavior |
GO_0045087 | Biological process | innate immune response |
GO_0006396 | Biological process | RNA processing |
GO_0051607 | Biological process | defense response to virus |
GO_0035264 | Biological process | multicellular organism growth |
GO_0007274 | Biological process | neuromuscular synaptic transmission |
GO_0050884 | Biological process | neuromuscular process controlling posture |
GO_0045070 | Biological process | positive regulation of viral genome replication |
GO_0021618 | Biological process | hypoglossal nerve morphogenesis |
GO_0097049 | Biological process | motor neuron apoptotic process |
GO_0030336 | Biological process | negative regulation of cell migration |
GO_0060384 | Biological process | innervation |
GO_0021610 | Biological process | facial nerve morphogenesis |
GO_0051726 | Biological process | regulation of cell cycle |
GO_0005730 | Cellular component | nucleolus |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0045202 | Cellular component | synapse |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0003729 | Molecular function | mRNA binding |
GO_0003726 | Molecular function | double-stranded RNA adenosine deaminase activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0003723 | Molecular function | RNA binding |
GO_0008251 | Molecular function | tRNA-specific adenosine deaminase activity |
GO_0005515 | Molecular function | protein binding |
GO_0003725 | Molecular function | double-stranded RNA binding |
Gene name | ADARB1 |
Protein name | Double-stranded RNA-specific editase 1 (EC 3.5.4.37) (RNA-editing deaminase 1) (RNA-editing enzyme 1) (dsRNA adenosine deaminase) Adenosine deaminase RNA specific B1 |
Synonyms | DRADA2 ADAR2 RED1 |
Description | FUNCTION: Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2 and GRIK2) and serotonin (HTR2C), GABA receptor (GABRA3) and potassium voltage-gated channel (KCNA1). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alter their functional activities. Edits GRIA2 at both the Q/R and R/G sites efficiently but converts the adenosine in hotspot1 much less efficiently. Can exert a proviral effect towards human immunodeficiency virus type 1 (HIV-1) and enhances its replication via both an editing-dependent and editing-independent mechanism. The former involves editing of adenosines in the 5'UTR while the latter occurs via suppression of EIF2AK2/PKR activation and function. Can inhibit cell proliferation and migration and can stimulate exocytosis. .; FUNCTION: [Isoform 1]: Has a lower catalytic activity than isoform 2. .; FUNCTION: [Isoform 2]: Has a higher catalytic activity than isoform 1. . |
Accessions | ENST00000389861.7 [P78563-2] ENST00000705392.1 A0A994J7T5 ENST00000705393.1 ENST00000389863.8 [P78563-3] ENST00000360697.4 [P78563-1] ENST00000496664.5 [P78563-1] ENST00000437626.5 [P78563-1] ENST00000492414.5 [P78563-2] ENST00000449478.2 ENST00000348831.9 [P78563-2] P78563 ENST00000449478.2 [P78563-1] A0A0A0MSG8 A0A994J4V7 |